By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings - 2Watch SpaceX launch 119 payloads to orbit from California early on March 30
- 3Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- 4In wrangling dark matter, some scientists find inspiration in the Torah, Krishna and Christ
- 5Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- Germany unveils rescue plan for struggling chemical sector
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- The Strait of Hormuz Isn’t Just an Oil Problem, It’s Now a Food Problem
- Red Crescent: More than 100,000 civilian structures damaged in Iran
- 6 Eyewear Brands Worth Purchasing
- WHO issues guidance on GLP-1 drugs for obesity
- Surf Spot Mechanics: Bells Beach
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
